Clinical Trials
24 trialsNCT06802835 2026-05-11
EGFR Antibody Combined With PD-1 Inhibitor and Chemotherapy in R/M Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 1/2 Recruiting
NCT07524413 2026-04-13
Becotatug Vedotin (MRG003) With PD-1 Blockade and Chemoradiotherapy in High-Risk Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07385079 2026-02-03
Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT07373990 2026-01-28
Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Not yet recruiting
NCT04004871 2025-12-11
Induction Chemotherapy With Nab-paclitaxel, Cisplatin and Fluorouracil for Locoregionally Advanced Nasopharyngeal Carcinoma
Guangxi Medical University
Phase 2 Completed
NCT05305131 2025-09-23
Randomised Trial of Induction Gemcitabine and Cisplatin Versus Gemcitabine, Cisplatin, Pembrolizumab and Bevacizumab (GPPB) in Nasopharyngeal Cancer
National University Hospital, Singapore
Phase 2 Recruiting
NCT06749899 2025-05-22
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Sun Yat-sen University
Phase 3 Recruiting
NCT05587374 2025-01-23
GEMSTONE
Sun Yat-sen University
Phase 3 Active not recruiting
NCT03840421 2025-01-13
GP Vs PF As Induction Chemotherapy Combined with CCRT for Locoregionally Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Active not recruiting
NCT02113878 2024-11-05
Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Dana-Farber Cancer Institute
Phase 1 Completed
NCT06019130 2024-05-16
NPC-Nivo
German Society for Pediatric Oncology and Hematology GPOH gGmbH
Phase 2 Recruiting
NCT03700476 2023-03-28
CONTINUUM
Sun Yat-sen University
Phase 3 Unknown
NCT03837808 2022-11-07
Radiotherapy Plus Concurrent Nimotuzumab or Cisplatin in Stage II-III Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Unknown
NCT00370890 2022-02-17
A Trial of Adjuvant Chemotherapy in Nasopharyngeal Carcinoma Patients With Residual Epstein-Barr Virus (EBV) DNA Following Radiotherapy
Chinese University of Hong Kong
Phase 3 Completed
NCT01528618 2021-10-04
Effect and Safety Study of GP/FP Regimens in Advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 3 Completed
NCT04446663 2020-06-25
Toripalimab Combined With Chemoradiotherapy in Patients With Locoregionally-advanced Nasopharyngeal Carcinoma
First People's Hospital of Foshan
Phase 2 Unknown
NCT02444949 2020-06-24
A Trial of Endostar in Combination With Chemotherapy of DF and Sequential Intensity Modulated Radiation Therapy for Patients With Advanced Nasopharyngeal Carcinoma
China Three Gorges University, Yichang, China
Phase 2 Completed
NCT02627807 2020-06-16
Clinical Target Volume Based on Disease Extension Risk Atlas and Computer-aided Delineation in Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase NA Unknown
NCT00603915 2019-02-28
A Study of Gemcitabine and Cisplatin/Carboplatin Plus Erlotinib in Patients With Nasopharyngeal Cancer
University Health Network, Toronto
Phase 2 Completed
NCT03619824 2018-10-09
PD-1 Blockade Combined With Definitive Chemoradiation in Locoregionally-advanced Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Unknown
NCT03175939 2017-06-05
Elimination of Adjuvant Chemotherapy for Selected Stage II and III Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT02360501 2016-04-20
Combination of Docetaxel, Cisplatin, and Capecitabine (DCX) in the Treatment of Nasopharyngeal Carcinoma
Sun Yat-sen University
Phase 2 Completed
NCT00747799 2013-12-10
Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Failed With Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 2 Completed
NCT01312311 2011-03-10
Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer
Samsung Medical Center
Phase 2 Unknown